INTERNATIONAL PATENT: TAKEDA PHARMACEUTICAL COMPANY LIMITED FILES APPLICATION FOR "4H-PYRIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR USE AS NLRP3 INFLAMMASOME INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDER"

GENEVA, Nov. 17 -- TAKEDA PHARMACEUTICAL COMPANY LIMITED (1-1 Doshomachi 4-chome, Chuo-kuOsaka-shi, Osaka 541-0045) filed a patent application (PCT/IB2025/054740) for "4H-PYRIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR USE AS NLRP3 INFLAMMASOME INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDER" on May 06, 2025. With publication no. WO/2025/233837, the details related to the patent application was published on Nov 13, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): MIKAMI, Satoshi (c/o Takeda Pharmaceutical Company Limited26-1, Muraoka-Higashi 2-ChomeFujisawa-Shi, Kanagawa 251-0012), ...